Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate 35 mg versus 70 mg weekly for osteopenia in postmenopausal women
IRCT20190325043111N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of alendronate in osteopenia (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: FRAX, Hip T-score and 3 more. Started Apr 2015; status: completed.
02
Drugs
alendronate
03
Conditions
osteopenia
Beyond the preview
Go deeper on IRCT20190325043111N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190325043111N1.